641 results about "Immunogen" patented technology

The invention belongs to the field of veterinary biotechnology detection, and particularly relates to a hybridoma cell strain and a monoclonal antibody for detecting or identifying MDV-1 and application of the hybridoma cell strain and the monoclonal antibody. The hybridoma cell strain MDV-1Mab-pp38-E2 is obtained through screening by taking pp38 protein of MDV-1 as immunogen, the preservation number is CCTCC NO: C202501, the monoclonal antibody generated by the hybridoma cell strain can recognize I-type chicken Marek's disease virus strains with different serum, and the monoclonal antibody can be used for identifying the type I chicken Marek's disease virus strains with different serum types. The kit has good specificity and sensitivity and can be used for exogenous virus detection of the serum type I chicken Marek's disease virus in poultry virus live vaccines without cross reaction with serum type II chicken Marek's disease virus, serum type III chicken Marek's disease virus, chicken egg drop syndrome virus (EDSV) and other common poultry disease viruses, and the kit has good specificity and sensitivity and can be applied to exogenous virus detection of the serum type I chicken Marek's disease virus in poultry virus live vaccines. The kit can also be used for clinical identification, virus content determination and epidemiological investigation of serotype I chicken Marek's disease virus.

The invention discloses an anti-human inflammatory factor interleukin 6 monoclonal antibody and an application thereof. When the monoclonal antibody is prepared, an adopted immunogen is a human inflammatory factor interleukin 6 antigen, and an amino acid sequence of the human inflammatory factor interleukin 6 antigen comprises a sequence as shown in SEQ ID NO: 1. A group of monoclonal antibodies specifically combined with antigens is constructed based on the IL-6 antigens. The IL-6 monoclonal antibody has strong binding capacity with an IL-6 antigen in a clinical sample, has no cross reaction with other proteins, has good specificity and affinity compared with a commercial antigen, can be effectively applied to ELISA and a dry-type immunofluorescence method, has good detection linearity, precision, stability and accuracy, and can be widely applied to the field of immunoassay. The antibody can be combined with the antigen to serve as a detection reagent raw material combination, and has clinical detection advantages.

Compositions are provided, of the general formula X1-X2-X3, wherein (a)X2 comprises an antigen; (b) X1 is absent or comprises or consists of the amino acid sequence (C)KKKTG (SEQ ID NO: 1); and (c) X3 is absent or comprises or consists of the amino acid sequence GTKKK(C) (SEQ ID NO:2), wherein (i) only one of X1 and X3 is present, and (ii) the residue m parentheses m SEQ ID NO: 1 and SEQ ID NO: 2 is optional and may be present or may be deleted.

This disclosure generally relates to methods and compositions for eliciting broad and robust immune responses to a protein of interest. The methods employ both DNA and RNA-based vaccines that encode at least a portion of the protein of interest.

The invention relates to the technical field of biological medicine, in particular to immunogen cell death enhanced nano-vesicle hydrogel and application thereof. The invention provides a 3D-printable multifunctional synergistic immunogen cell death enhanced nano-vesicle hydrogel, which is characterized in that SerMA hydrogel is used as a matrix, cell membrane nano-vesicles (N (at) ILO) loaded with a photothermal agent IR1061, a chemotherapeutic drug OXA and a tumor acidic microenvironment regulator Lon are encapsulated, initial tumor immunogen cell death is triggered through a photothermal effect, and the tumor immunogen cell death enhanced nano-vesicle hydrogel can be used for 3D printing. OXA further enhances the ICD effect, Lon regulates the acidic tumor microenvironment to improve the T cell activity, and postoperative multi-mode synergistic anti-tumor treatment is achieved; meanwhile, the hydrogel also has excellent photocuring 3D printing capability, can be used for individually constructing a filling structure matched with a postoperative defect area, has a wide application prospect, and provides a new strategy and theoretical basis for postoperative comprehensive treatment of choroidal melanoma.

The invention provides an ORM1 and CEA protein antibody, a combination of the ORM1 and CEA protein antibody and an application of the ORM1 and CEA protein antibody in colorectal cancer diagnosis, and aims to effectively solve the problems of low affinity and specificity and poor stability of the existing antibody by optimizing the immunogen sequences of ORM1 and CEA, screening a monoclonal antibody with high affinity and high specificity, screening the optimal ORM1 and CEA antibody and combining the optimal ORM1 and CEA antibody. The kit has a wide detection range, shows an extremely high collaborative diagnosis value during combined detection, remarkably improves the diagnosis efficiency of early colorectal cancer, and has an important clinical application value.

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. Some methods, such as when a subject has preexisting against an immunogen to be administered, use plasma cell depleting agents or combinations comprising plasma cell depleting agents to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting. Other methods, such as when a subject has no preexisting immunity against an immunogen to be administered, use B cell depleting agents (e.g., anti-CD20xCD3 antibody or functional fragment thereof) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting.

The invention discloses a rabbit polyclonal antibody for specific recognition of ANP32a K236 milk acylation modification and application of the rabbit polyclonal antibody. The rabbit polyclonal antibody is prepared by taking modified polypeptide as an immunogen and immunizing animals. The amino acid sequence of the adopted modified polypeptide is as shown in SEQ ID NO.1, and the 7th site in the amino acid sequence is modified by a lactic acid group and is CGSQKR-(lactyl) K-REPDD. The rabbit polyclonal antibody has high specificity and high sensitivity, can be used for detecting the milk acylation modification of the K236 site of the ANP32a protein, and fills the blank of detection tools in the field.

The present invention provides engineered soluble F proteins of paramyxoviruses, such as respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and human parainfluenza virus (hPIV). These engineered proteins are stabilized by specific modifications in the wild-type soluble F sequence, such as substitutions in the 023 chain and / or the introduction of engineered disulfide bonds in the 0 hairpin in the F1 subunit. The present invention also provides a nanoparticle vaccine comprising an engineered soluble F immunogen displayed on a self-assembled nanoparticle. The invention also provides methods of using such vaccine compositions in a variety of therapeutic applications, e.g., methods for preventing or treating viral infections, such as RSV, MPV, and PIV infections.

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.

The invention discloses an anti-soluble transferrin receptor monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of antibody detection. According to the antibody, an L101-F760 amino acid sequence of human TfR protein is used as an immunogen, specific screening of B cells, reverse RNA (Ribonucleic Acid) into cDNA (Complementary Deoxyribose Nucleic Acid) through RT-PCR (Reverse Transcription-Polymerase Chain Reaction), then homologous recombination is performed to construct heavy and light chain vectors, and finally multiple rounds of screening are performed to obtain the purified sTfR monoclonal antibody, so that the sTfR protein can be specifically recognized, and the antibody has the advantages of high specificity and high sensitivity and can be widely applied to the field of immunotherapy. The natural sTfR protein in human serum can be recognized. The kit is applied to the detection and screening fields of immunohistochemistry, immunofluorescence chemistry, western blot, co-immunoprecipitation, indirect ELISA, flow cytometry and the like, especially has low background and no interference of non-specific binding impure protein during immunohistochemistry detection, can obtain more accurate detection and evaluation results, avoids interference of false positive and false negative, and has high detection accuracy. The method has great application value in the aspects of basic scientific research and clinical pathology detection.

The invention relates to the technical field related to immunological detection, in particular to a mouse anti-porcine herpesvirus type 1 gE monoclonal antibody as well as an immunogen and application of the mouse anti-porcine herpesvirus type 1 gE monoclonal antibody. The amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: GFSLSTSGMG, IVWGSETGRVTISRDNSK and VRYYDGDDD, and the amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: KSSQSLLYSDGKTFLN, LGSNRAS and SSLPHED. The monoclonal antibody can be specifically combined with gE proteins of all subtypes of the porcine herpesvirus type 1, and a porcine herpesvirus type 1 detection kit prepared from the monoclonal antibody has the advantages of high sensitivity, strong specificity, wide detection range, short detection time and the like.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

The invention relates to a monkey pox virus nano vaccine based on an STING agonist and silicon nanoparticles as well as a preparation method and application of the monkey pox virus nano vaccine. The nano vaccine comprises a monkey pox virus antigen, the silicon nanoparticles and the STING agonist, the monkey pox virus antigen is combined to the surface of the silicon nanoparticle through a DogTag-DogCatcher system; the STING agonist is connected to the surface of the monkey pox virus antigen. The monkey pox virus antigen is covalently coupled with the silicon nanoparticles, and the antigen is displayed on the surfaces of the particles in a specific spatial orientation manner, so that the multivalence and accessibility of the antigen are enhanced, the shielding effect of the silicon nanoparticles on epitopes of the antigen is reduced, and the immune response induced by the vaccine is higher than that of a monomer immunogen protein.

The invention provides synthesis of a T-2 toxin antigen and preparation and application of a monoclonal antibody. Relates to the technical field of biotoxin detection. The preparation method of the T-2 toxin antigen comprises the following steps: step 1, synthesizing an immunogen T-2-BSA by adopting a carbodiimide method, dissolving 2mg of T-2 adipic acid with 0.5 mL of dimethylformamide, and recording as a solution A; 5 mg of bovine serum albumin and 3 mg of EDC are dissolved with a 2-morpholine ethanesulfonic acid buffer solution with the pH being 5.5, and the solution is marked as a solution B; step 2, under the condition of stirring, dropwise adding the solution A into the solution B, stirring for 18 hours in a dark place at 4 DEG C, then dialyzing for 3 days by using a phosphate buffer solution, changing the solution once a day, centrifuging the dialysate for 10 minutes at 3,500 r / min, and discarding the precipitate; the adipic acid is coupled with the T-2 toxin through a chemical method, and the unique step enriches the structural characteristics of the hapten, so that the prepared T-2 toxin complete antigen is excellent in immune effect, can efficiently excite immune response of an organism, and shows high specificity and sensitivity.

The invention relates to the technical field of hepatocellular carcinoma, in particular to a hepatocellular carcinoma prognosis model construction method based on immunogen cell death related genes and application, and an accurate prognosis prediction model is constructed by integrating the immunogen cell death related genes (IRGs) and molecular characteristics of hepatocellular carcinoma. A training set and a verification set provided by TCGA and ICGC databases are utilized, so that the model can perform effective sample analysis under a large-scale data background. Through consistency clustering analysis, the optimal clustering number is determined, the samples are orderly divided into different molecular subtypes, and it is ensured that the samples in each subtype have similar molecular characteristics. According to the invention, the capability of capturing liver cancer heterogeneity on the molecular level of the model is increased, so that the accuracy of prognosis prediction is improved.

The present invention relates to a recombinant chimeric antigen targeting poxvirus (particularly monkeypox virus), a subunit vaccine thereof, and its application. The recombinant chimeric antigen of the present invention comprises two immunogens arranged in a specific manner: monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment) and monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), which can stimulate immune responses against two infectious virus particles: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently stimulating specific immune protection against monkeypox virus. In addition, the poxvirus vaccine of the present invention also has good safety, rapid responsiveness and production capacity support, and has excellent clinical application prospects.

The invention discloses a nano antibody for resisting a listeria monocytogenes MurA protein and application of the nano antibody, and relates to the technical field of biology. The amino acid sequence of the nano antibody is as shown in SEQ ID NO.3. MurA protein of prokaryotically expressed listeria monocytogenes is used as an immunogen to immunize alpaca, total RNA of peripheral blood lymphocytes is extracted, VHH fragments are amplified through reverse transcription and two rounds of nested PCR, the VHH fragments and a pComb3Xss vector are converted into TG1 competent cells after enzyme digestion and connection, and a phage display technology is used for three rounds of elutriation, so that the total RNA of the listeria monocytogenes is obtained. The nanometer antibody for resisting the listeria monocytogenes MurA protein is successfully screened out. The nano antibody can specifically recognize MurA protein and whole listeria monocytogenes, and the immunocolorimetric sensor based on thiolated bacteriophage induced colloidal gold aggregation, which is established by utilizing the nano antibody, is strong in specificity, high in sensitivity and low in detection limit, and can greatly shorten the detection time.

The invention relates to germline-targeting designs, stabilization designs, and / or combinations thereof, of proteins designed with modified surfaces helpful for immunization regimens, other protein modifications and / or development of nanoparticles, methods of making and using the same, and to (a) germline-targeting priming or boosting / shepherding immunogens to initiate or guide maturation of VRC01-class responses (b) PCT64 / PG9-germline-targeting designs (c) BG18-germline-targeting designs or boosting / shepherding immunogens to initiate or guide maturation of BG18-like responses, and / or (d) trimer stabilization and presentation in a membrane-bound format.

The invention relates to the technical field of biological medicines, and discloses a PD-L1 K263 acetylation modified antibody, which is prepared from an immunogen containing a sequence as shown in SEQ ID NO.1. The PD-L1 K263 acetylation modified antibody is a PD-L1 K263 acetylation modified antibody. The invention also discloses a preparation method of the PD-L1 K263 acetylation modified antibody. The preparation method comprises the following steps: designing and synthesizing a polypeptide antigen, preparing an immunogen, immunizing animals, purifying the antibody and evaluating serum titer. The antibody provided by the invention can accurately recognize and combine with the PD-L1 protein subjected to K263 acetylation modification in the breast cancer, provides a specific tool for qualitative and quantitative detection of K263Ac-PD-L1 in the breast cancer, and provides a reliable molecular marker detection means for evaluating the curative effect of anti-PD-1 / PD-L1 immunotherapy; therefore, a biological preparation with specificity and practicability and a technical support are provided for accurate diagnosis, targeted therapy and curative effect monitoring of breast cancer.

The invention provides a Garlu virus attenuated strain and application thereof, and relates to the field of virology and biological medicine. According to the invention, the screened Garlu virus attenuated strain is a natural attenuated strain derived from a tick sample, can grow in Vero cells, has the titer of more than or equal to 107 TCID50 / mL, does not have clinical pathogenicity to an immunodeficient host, and is safe; after the attenuated strain is used as an immunogen for pre-intervention, infection of a lethal virus strain can be avoided, the survival rate is increased to 100%, adverse effects on growth and life of experimental animals are avoided, particularly, a host can be stimulated to generate humoral immunity and cellular immunity at the same time, and the survival rate of the experimental animals is improved. And moreover, broad-spectrum cross-protection efficacy can be generated on Bandavirus lethal virus strains, and a foundation is laid for improvement of research on Bandavirus live vaccines such as the Colu virus and the like.

The invention discloses a preparation method and application of a cat main allergen FEL-1 nano antibody FEL-1-Nb, and relates to the technical field of antibody preparation, and the preparation method comprises the following steps: preparing an immunogen; animal immunization and library construction; constructing and panning a phage display library; screening and identifying positive clone; and expression and purification of the nano antibody: cloning the positively cloned VHH gene to an expression vector such as a pET series, transforming an expression strain such as escherichia coli BL21 (DE3), carrying out IPTG induced expression, and purifying through an inclusion body purification method to obtain a high-purity nano antibody protein. The nano antibody FEL-1-Nb provided by the invention can be specifically bound with a cat main allergen FEL-1 protein, the unique amino acid sequence of the nano antibody FEL-1-Nb is shown as SEQIDNO: 1, high-affinity binding with the FEL-1 protein is ensured, the positive clone binding rate is high through phage display panning and ELISA verification, the phage recovery rate after the third round of panning is increased by more than 1000 times compared with the first round of panning, and the positive clone binding rate is higher than that of the first round of panning. Therefore, the nano antibody has excellent targeted recognition capability.

The invention relates to a preparation method of a p-cresol sulfate (PCS) detection kit by using a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a p-cresol sulfate (PCS) detection kit. P-cresol sulfate is a protein-bound uremic toxin in a human body, has small molecular weight and poor immunogenicity, and when a corresponding antibody is prepared, a hapten and a specific macromolecular carrier need to be coupled to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a sulfuric acid p-cresol hapten, preparation of a sulfuric acid p-cresol complete antigen and an anti-sulfuric acid p-cresol antibody, a method for measuring the concentration of sulfuric acid p-cresol, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a sulfuric acid p-cresol derivative. The p-cresol sulfate derivative disclosed by the invention has a structure as shown in a formula (I): # imgabs0 #, wherein R is-(CH2) n-COOH, and n is 4.

The invention relates to the technical field of biology, in particular to an anti-porcine CD82 protein monoclonal antibody, a hybridoma cell strain and application, the monoclonal antibody is prepared by the following steps: expressing and purifying a CD82 (EC2) region by utilizing a prokaryotic expression system, preparing by taking the purified recombinant protein as an immunogen, and carrying out indirect ELISA (enzyme-linked immuno sorbent assay) and Flow Cytometry screening to obtain the monoclonal cell strain capable of secreting an IgG2a type antibody. The purified antibody is detected through an indirect ELISA method, sensitive reaction still exists when the antibody concentration reaches 31.25 ng / ml, PAM cells capable of expressing endogenous CD82 protein are detected through flow cytometry, and the result shows that the mAb has good marking capacity for the PAM cells, indicating that the mAb of the CD82 protein capable of being used for flow cytometry is successfully prepared. A biological tool is provided for further analyzing the function and mechanism of the CD82 protein.

The invention relates to a construction method of a nanometer antibody coding DNA library. The method comprises the following steps: screening animal peripheral blood mononuclear cells (PBMC) by using immunogen to obtain positive cells specifically bound with the immunogen; and amplifying a nucleic acid sample derived from the positive cells so as to obtain a coding DNA library of the nano-antibody, wherein the nano antibody is a nano antibody specifically binding to the immunogen, and wherein the amplification comprises the use of one or more groups of primer pairs, each group of primer pairs of the one or more groups of primer pairs comprising one or more forward primers and one or more reverse primers. A large number of diversified DNA sequences covering a large number of low-abundance sequences are obtained. According to the technical route for rapidly preparing the VHH antibody based on high-throughput sequencing, the high-affinity and high-specificity VHH antibody can be efficiently and rapidly obtained, and the raw material requirement of a high-quality diagnostic reagent is met.

The invention relates to molecular glue for forming fimbriae related protein based on SpaA isopeptide bonds of Vinci bacteria. The invention also relates to a nanoparticle vaccine composition formed by the molecular glue, and the immunogen is covalently displayed on the surface of the nanoparticle by the molecular glue.

The present invention relates to anti-ILT7 antibodies. Antibodies capable of binding to IPC are obtained by using animal cells in which a cell membrane protein that binds to ILT7 is co-expressed as an immunogen. The antibodies of the present invention have high specificity, such that the antibodies can immunologically distinguish ILT7 from other ILT family molecules. The anti-ILT-7 antibodies of the present invention can bind to IPC and inhibit its activity. The activity of IPC can be inhibited by the anti-ILT-7 antibodies of the present invention, and interferon-related diseases can be treated or prevented. In the presence of IFNα, the expression of ILT7 in IPC can still be maintained. Therefore, in patients with various autoimmune diseases with increased IFNα production, an inhibitory effect of anti-ILT-7 antibodies on the activity of IPC can be expected.

Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and / or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and / or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.